A smarter insulin that aims for the liver could curb dangerous nighttime dips

NCT ID NCT06238778

Completed Disease control Sponsor: Diasome Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This trial tests whether a specially designed mealtime insulin, HDV-insulin lispro, can reduce nighttime low blood sugar (hypoglycemia) in adults with type 1 diabetes. Participants will use continuous glucose monitors and work with doctors to adjust doses. One group receives the liver-targeted insulin, while the other uses standard insulin lispro. The study lasts up to 32 weeks and also tracks blood fats and liver enzymes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HDV-Insulin lispro, a liver-targeted form of mealtime insulin
What this could lead to: If successful, this approach could reduce dangerous nighttime low blood sugar episodes in people with type 1 diabetes, improving safety and quality of life.
What could go wrong: This is an early-phase trial, so results may not hold up in larger studies. The liver-targeting insulin may not perform better than standard insulin and could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus type 1 diabetes mellitus 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 1

Contacts and locations

Locations

Asheville Clinical Research

Asheville, North Carolina, 28803, United States
Atlanta Diabetes Associates

Atlanta, Georgia, 30318, United States
Clinical Trials of Texas

San Antonio, Texas, 78229, United States
Diabetes Research Center

Tustin, California, 92780, United States
East Coast Institute for Research

Jacksonville, Florida, 32216, United States
East Coast Institute for Research

Canton, Georgia, 30114, United States
Endeavor Health

Skokie, Illinois, 60077, United States
Endocrine Research Solutions, Inc.

Roswell, Georgia, 30076, United States
Indiana Medical Research Institute

Merrillville, Indiana, 46410, United States
Marvel Clinical Research

Huntington Beach, California, 92647, United States
Metabolic Research Institute

West Palm Beach, Florida, 33401, United States
Pasadena Clinical Trials

Pasadena, California, 91101, United States
Physician's East

Greenville, North Carolina, 27834, United States
Physicians Research Associates, LLC

Lawrenceville, Georgia, 30046, United States
SUNY Upstate Medical University

Syracuse, New York, 13210, United States
Tekton Research, LLC

Irving, Texas, 75039, United States
Tekton Research, LLC

McKinney, Texas, 75069, United States
Tekton Research, LLC

San Antonio, Texas, 78251, United States
Texas Diabetes % Endocrinology

Round Rock, Texas, 78681, United States
Texas Diabetes & Endocrinology

Austin, Texas, 78749, United States
UNC EnDO Clinical Research Unit

Chapel Hill, North Carolina, 27514, United States
University Hospitals Medical Center

Cleveland, Ohio, 44106, United States
University of Chicago Kovler Diabetes Center

Chicago, Illinois, 60637, United States
University of Colorado, Barbara Davis Center

Denver, Colorado, 80045, United States
University of Miami Diabetes Research Institute

Miami, Florida, 33136, United States
Virginia Endocrinology Research

Chesapeake, Virginia, 23321, United States
Wasatch Clinical Research, LLC 310

Salt Lake City, Utah, 84107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.